Andrew Heron

Andrew Heron earned his PhD in chemical biology from Imperial College London and conducted post-doctoral research at the University of Oxford’s Department of Chemistry. A leading expert in nanopore technology and single-molecule methods, he has over 20 years of experience developing advanced single-molecule biosensing platforms. At Oxford University, he co-led foundational research that contributed to the development of nanopore DNA sequencing technology, later licensed and further developed by Oxford Nanopore Technologies. Joining Oxford Nanopore in 2010, Andrew played a key role as a senior team member in the development and commercialization of its DNA and RNA sequencing technologies.

Now the founder and CEO of Portal Biotech, he is focused on pioneering the development of a next-generation nanopore platform technology for proteomic and metabolomic characterization and sequencing.